BB
AGIO icon

BB Biotech’s Agios Pharmaceuticals AGIO Stock Holding History

BB Biotech’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$201M Buy
2,978,134
+100,000
+3% +$5.82M 5.05% 7
2018
Q4 		$133M Buy
2,878,134
+680,203
+31% +$42M 4.25% 7
2018
Q3 		$170M Hold
2,197,931
– – 4.49% 7
2018
Q2 		$185M Sell
2,197,931
-337,322
-13% -$29.4M 5.35% 6
2018
Q1 		$207M Sell
2,535,253
-184,745
-7% -$14.3M 5.73% 7
2017
Q4 		$156M Sell
2,719,998
-30,000
-1% -$1.89M 4.38% 12
2017
Q3 		$184M Sell
2,749,998
-119,530
-4% -$7.18M 5.08% 9
2017
Q2 		$148M Buy
2,869,528
+30,000
+1% +$1.53M 4.51% 9
2017
Q1 		$166M Buy
2,839,528
+30,000
+1% +$1.44M 5.42% 6
2016
Q4 		$117M Buy
2,809,528
+160,000
+6% +$8.4M 4.34% 9
2016
Q3 		$140M Buy
2,649,528
+286,207
+12% +$12.5M 4.92% 8
2016
Q2 		$99M Buy
2,363,321
+203,400
+9% +$10M 3.91% 10
2016
Q1 		$87.7M Hold
2,159,921
– – 3.49% 10
2015
Q4 		$140M Buy
2,159,921
+50,000
+2% +$3.28M 3.95% 9
2015
Q3 		$149M Buy
2,109,921
+120,000
+6% +$11.7M 4.72% 7
2015
Q2 		$221M Buy
1,989,921
+140,000
+8% +$15.1M 6% 6
2015
Q1 		$174M Sell
1,849,921
-15,000
-0.8% -$1.68M 5.2% 5
2014
Q4 		$209M Sell
1,864,921
-25,600
-1% -$2.29M 6.77% 5
2014
Q3 		$116M Buy
1,890,521
+1,384,521
+274% +$59.7M 4.72% 8
2014
Q2 		$23.2M Buy
+506,000
New +$20.6M 1.1% 18

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech's AGIO Position: Q1 2019 in Review

BB Biotech increased its Agios Pharmaceuticals (AGIO) stake by 3.5% in Q1 2019, buying an estimated $5.82M and bringing the position to 2,978,134 shares worth $201M. The position accounts for 5.05% of the portfolio, ranked #7.

BB Biotech first reported a position in AGIO in Q2 2014 and has held it in 20 quarters since. The position peaked at $221M in Q2 2015. 201 funds tracked by Wall St. Rank hold AGIO as of Q1 2019.

  • BB Biotech held 2,978,134 shares of Agios Pharmaceuticals worth $201M as of Q1 2019.
  • BB Biotech bought 100,000 Agios Pharmaceuticals shares in Q1 2019, an estimated $5.82M.
  • Agios Pharmaceuticals made up 5.05% of BB Biotech's portfolio in Q1 2019, its #7 holding.
  • BB Biotech first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 20 quarters since.
  • BB Biotech's Agios Pharmaceuticals position peaked at $221M in Q2 2015.
  • 201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.